SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccineCoronaVac 또는 BNT162b2 백신의 3차 추가 접종 후 의료 종사자의 SARS-CoV-2 특이 항체 반응Article Published on 2022-08-012022-09-12 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 진단, [키워드] adverse event Antibody Response Antibody titer BNT162b2 BNT162b2 vaccine booster dose chose CoronaVac Day eligible evaluate female HCW HCWs healthcare worker humoral Immunoglobulin Immunoglobulin G inactive individual male marker median Ministry of Health mRNA vaccine participant reported SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG antibody SARS-CoV-2 vaccination serum significant difference Sinovac the S1 subunit the spike protein Turkey vaccination Vaccine virus were given [DOI] 10.1002/jmv.27794 PMC 바로가기 [Article Type] Article
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in SingaporeArticle Published on 2022-08-012022-11-16 Journal: JAMA Network Open [Category] SARS, 변종, [키워드] 95% CI adjusted Against age Assessing BBIBP-CorV BNT162b2 booster cohort study Combination combinations CoronaVac COVID-19 COVID-19 vaccination death defined determine dose Effectiveness eligible Estimated greater homologous inactivated individual Infection intensive care Moderna mRNA mRNA COVID-19 vaccine mRNA vaccine mRNA-1273 no significant difference Older omicron outcome Pfizer-BioNTech provided reduction Reinfection SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 variant severe COVID-19 severe disease Sex Singapore Sinopharm Sinovac supplemental oxygen time interval vaccination Vaccine vaccine dose waned was determined were excluded women [DOI] 10.1001/jamanetworkopen.2022.28900 PMC 바로가기
Vaccines for Covid-19: An insight on their effectiveness and adverse effectsReview Published on 2022-08-012023-06-20 Journal: Journal of medical virology [Category] Fulltext, MERS, [키워드] Efficacy relative risk rate SARS-COVID 19 Sinovac Vaccines [DOI] 10.1002/jmv.27810 PMC 바로가기 [Article Type] Review
Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis2~21세의 건강하고 면역이 억제된 소아 및 청소년을 대상으로 한 코로나19 감염에 대한 백신의 면역학적 반응, 효능 및 안전성: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-08-012022-09-11 Journal: Journal of Clinical Virology [Category] 변종, 임상, [키워드] abort Adenovirus Adolescent adolescents Adverse reaction Adverse reactions assessment BBIBP-CorV BNT162b2 children clinical trials collected conditions CoronaVac COVID-19 COVID-19 pandemic COVID-19 vaccination Efficacy evaluated healthy children immune response immune systems immunization Immunologic Immunosuppressed JNJ-78436735 Mental Meta-analysis Moderna mRNA mRNA-1273 myocarditis Myopericarditis outcomes participant Pfizer physical Prevent proportion PROSPERO Registered reported resolved review Safety safety profile second dose Severe infection Sinopharm Sinovac suppressed systematic review Transmission underlying disease underlying diseases vaccination Vaccine variant vectored vaccine [DOI] 10.1016/j.jcv.2022.105196 PMC 바로가기 [Article Type] Meta-Analysis
Vaccination Is Associated With Shorter Time to Target Cycle Threshold Value in Patients With SARS-CoV-2 Omicron Variant백신 접종은 SARS-CoV-2 오미크론 변이가 있는 환자에서 목표 주기 역치 값까지 더 짧은 시간과 관련이 있습니다.Article Published on 2022-07-062022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age Alter BBIBP-CorV booster vaccination Characteristics China Chinese CoronaVac coronavirus Course cycle cycle threshold Cycle threshold value disease course had no heterogeneous homologous inactivated Inactivated Vaccines infected with SARS-CoV-2 Infection Isolation life Limited male Mild symptom mild symptoms no difference omicron Omicron variant Patient patients patients with SARS-CoV-2 response retrospective cohort SARS-CoV-2 Science severe acute respiratory syndrome Coronavirus Shanghai Sinopharm Sinovac subject target the disease the mean time vaccination Vaccines value variant [DOI] 10.3389/fcimb.2022.943407 PMC 바로가기 [Article Type] Article
COVID-19: vaccination vs. hospitalizationMulticenter Study Published on 2022-06-012023-07-07 Journal: Infection [Category] COVID19(2023년), [키워드] BioNTech COVID-19 pandemic COVID-19 vaccine Sinovac [DOI] 10.1007/s15010-021-01751-1 PMC 바로가기 [Article Type] Multicenter Study
The assesment of retina and optic disc vascular structures in people who received CoronaVac vaccineArticle Published on 2022-06-012023-07-08 Journal: Photodiagnosis and photodynamic therapy [Category] COVID19(2023년), [키워드] CoronaVac coronavirus COVID-19 Optical coherence tomography angiography Sinovac [DOI] 10.1016/j.pdpdt.2022.102742 PMC 바로가기
Evaluation of antibody response after two doses of the Sinovac vaccine and the potential need for booster doses in cancer patientsArticle Published on 2022-06-012023-07-08 Journal: Journal of medical virology [Category] COVID19(2023년), [키워드] Cancer COVID-19 vaccine SARS-CoV-2 Sinovac [DOI] 10.1002/jmv.27665
Efficacy of antibody response following the vaccination of SARS-CoV-2 infected and noninfected healthcare workers by two-dose inactive vaccine against COVID-19COVID-19에 대한 2회 접종 불활성 백신에 의한 SARS-CoV-2 감염 및 비감염 의료 종사자의 백신 접종 후 항체 반응의 효능Article Published on 2022-06-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgG antibodies anti-SARS-CoV-2 IgG antibody antibody Antibody Response Antibody responses appearance classical Comorbidities concerning coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection Day demographics detect Efficacy first dose healthcare worker IgG antibodies IgG level IgG levels immunogenicity Immunosuppression inactive individuals infected with SARS-CoV-2 Infection information investigated majority Neutralizing activity positive postvaccination produced rapid increase SARS-CoV-2 screened second dose second vaccination seropositive seropositive individual seropositive individuals Seropositivity significantly higher Sinovac subject subjects Support Symptoms titers vaccination Vaccine virus [DOI] 10.1002/jmv.27649 PMC 바로가기 [Article Type] Article
Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events장내 미생물 조성은 SARS-CoV-2 백신 면역원성 및 부작용과 관련이 있습니다.Observational Study Published on 2022-06-012022-09-12 Journal: Gut [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] adverse event Anti-inflammatory antibody association Bacteria Bacterial baseline Bifidobacterium BNT162b2 BNT162b2 vaccine carbohydrate collected complement conducted CoronaVac COVID-19 COVID-19 vaccinee COVID-19 vaccines Effectiveness enteric bacterial microflora flagella Gut gut microbiota gut microbiota composition high neutralising antibody Host immune response IgG ELISA immune response Inactivated vaccine individual Intervention Linear Discriminant Analysis marker metabolism metagenomic sequencing Microbiome microbiota modulating mRNA vaccine pathway performed positive correlation Prevotella recipient reduced SARS-CoV-2 SARS-CoV-2 vaccine second dose significantly lower Sinovac spike receptor-binding domain Stool subject the vaccine vaccination Vaccine vaccinee vaccinees Virus neutralisation were measured [DOI] 10.1136/gutjnl-2021-326563 PMC 바로가기 [Article Type] Observational Study